Zelira Therapeutics Limited
ZLDAF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $1 | $95 | $301 | $1,541 |
| % Growth | -99.3% | -68.5% | -80.5% | – |
| Cost of Goods Sold | $804 | $85 | $3,517 | $7,257 |
| Gross Profit | -$803 | $10 | -$3,216 | -$5,716 |
| % Margin | -122,400.2% | 10.8% | -1,068% | -371% |
| R&D Expenses | $2,665 | $2,810 | $1,336 | $1,397 |
| G&A Expenses | $1,654 | $1,337 | $3,062 | $6,078 |
| SG&A Expenses | $485 | $1,337 | $3,062 | $6,078 |
| Sales & Mktg Exp. | $13 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1,801 | $1,776 | $224 |
| Operating Expenses | $3,149 | $5,949 | $6,174 | $7,699 |
| Operating Income | -$3,952 | -$5,938 | -$6,502 | -$13,415 |
| % Margin | -602,467.8% | -6,253.9% | -2,159.3% | -870.7% |
| Other Income/Exp. Net | $103 | -$31,721 | $233 | -$291 |
| Pre-Tax Income | -$3,850 | -$37,659 | -$6,269 | -$13,706 |
| Tax Expense | $0 | -$920 | $0 | -$1,292 |
| Net Income | -$3,628 | -$36,569 | -$5,573 | -$11,945 |
| % Margin | -553,029.3% | -38,513% | -1,850.8% | -775.4% |
| EPS | -0.32 | -3.22 | -0.55 | -1.49 |
| % Growth | 90.1% | -485.5% | 63.1% | – |
| EPS Diluted | -0.32 | -3.22 | -0.55 | -1.49 |
| Weighted Avg Shares Out | 11,483 | 11,347 | 10,068 | 8,042 |
| Weighted Avg Shares Out Dil | 11,483 | 11,347 | 10,068 | 8,042 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $11 |
| Interest Expense | $407 | $739 | $77 | $54 |
| Depreciation & Amortization | $270 | $479 | $424 | $474 |
| EBITDA | -$4,051 | -$35,521 | -$6,740 | -$11,886 |
| % Margin | -617,481.4% | -37,409.9% | -2,238.4% | -771.5% |